Abstract
Abstract
Introduction
The treatment landscape for the prevention of migraine has rapidly evolved in recent years with the advent of calcitonin gene-related peptide therapy, including erenumab. The objective of this study was to assess patient-reported treatment satisfaction among erenumab users.
Methods
This retrospective, cross-sectional study used data from the 2019 US National Health and Wellness Survey collected during March–July 2019. Respondents self-reporting physician-diagnosed migraine and currently using erenumab were analyzed. Treatment satisfaction was measured on a seven-point Likert scale. Data were further reported by the duration of erenumab treatment. Data on respondents’ socio-demographic characteristics and treatment patterns were also collected.
Results
Overall, 67 respondents using erenumab with or without other migraine preventives for up to 1 year were included in the analysis. The mean (standard deviation) age was 46.7 (12.9) years. Most of the respondents were women (86.6%), White (74.6%), and commercially-insured (67.2%). Notably, 40.3% had ≥1 comorbidity per the Charlson Comorbidity Index. Approximately half of the respondents were college graduates and employed (49.3% each). Among the 67 respondents, 46 received erenumab exclusively. Across both cohorts, the percentage of respondents who were satisfied with erenumab treatment was slightly higher among those with a longer treatment duration (overall erenumab cohort: 63.6%, 69.6%, and 75.8% for 0 to <3, 3 to <6, and 6 to 12 months, respectively; erenumab monotherapy cohort: 62.5%, 71.4%, and 87.5% for 0 to <3, 3 to <6, and 6 to 12 months, respectively). Treatment patterns before switching to erenumab revealed that most respondents had used ≥1 preventive treatment for migraine (80.6%; 54/67), over two-thirds (33/54) of whom had ≥2 treatment failures owing to nonresponse.
Conclusion
Satisfaction was high among long-term erenumab users, indicating that those using erenumab for a longer duration are more satisfied. Furthermore, this study provided insights on the basic socio-demographics, disease characteristics, and health behaviors of erenumab users as well as their treatment patterns before switching to erenumab.
Full text article
References
2. Rizzoli P, Mullally WJ: Headache. Am J Med. 2018, 131(1):17-24.
3. Agosti R: Migraine burden of disease: from the patient's experience to a socio-economic view. Headache. 2018, 58(S1):17-32.
4. Vo P, Fang J, Bilitou A, Laflamme AK, Gupta S: Patients’ perspective on the burden of migraine in Europe: a cross-sectional analysis of survey data in France, Germany, Italy, Spain, and the United Kingdom. J Headache Pain. 2018, 19(1):82.
5. Ong JJY, De Felice M: Migraine treatment: current acute medications and their potential mechanisms of action. Neurotherapeutics. 2018, 15(2):274-290.
6. Bigal ME, Serrano D, Reed M, Lipton RB: Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurol. 2008, 71(8):559-566.
7. Blumenfeld AM, Bloudek LM, Becker WJ, Buse DC, Varon SF, Maglinte GA, et al: Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache. 2013, 53(4):644-655.
8. Bonafede M, Wilson K, Xue F: Long-term treatment patterns of prophylactic and acute migraine medications and incidence of opioid-related adverse events in patients with migraine. Cephalalgia. 2019, 39(9):1086-1098.
9. Clark M, Schwedt TJ, Tepper SJ, Harris N, Martin S, Sapra S, et al: Patient satisfaction with prophylactic migraine medications. Headache. 2017, 57(Suppl 3):133.
10. Hepp Z, Bloudek LM, Varon SF: Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm. 2014, 20(1):22-33.
11. Hepp Z, Dodick DW, Varon SF, Chia J, Matthew N, Gillard P, et al: Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia. 2017, 37(5):470-485.
12. Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB: Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015, 35(6):478-488.
13. Martelletti P, Schwedt TJ, Lanteri-Minet M, Quintana R, Carboni V, Diener HC, et al: My Migraine Voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed. J Headache Pain. 2018, 19(1):115.
14. Woolley JM, Bonafede MM, Maiese BA, Lenz RA: Migraine prophylaxis and acute treatment patterns among commercially insured patients in the United States. Headache. 2017, 57(9):1399-1408.
15. Korolainen MA, Kurki S, Lassenius MI, Toppila I, Costa-Scharplatz M, Purmonen T, et al: Burden of migraine in Finland: health care resource use, sick-leaves and comorbidities in occupational health care. J Headache Pain. 2019, 20(1):13.
16. Do TP, Guo S, Ashina M: Therapeutic novelties in migraine: new drugs, new hope? J Headache Pain. 2019, 20(1):37.
17. Aimovig prescribing information [https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761077s000lbl.pdf]. Accessed 10 Dec 2020.
18. Barbanti P, Aurilia C, Egeo G, Fofi L: Erenumab: from scientific evidence to clinical practice-the first Italian real-life data. Neurol Sci. 2019, 40(Suppl 1):177-179.
19. Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V, et al: ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018, 38(6):1026-1037.
20. Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, et al: A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017, 377(22):2123-2132.
21. Lambru G, Hill B, Murphy M, Tylova I, Andreou AP: A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain. 2020, 21(1):61.
22. Ornello R, Casalena A, Frattale I, Gabriele A, Affaitati G, Giamberardino MA, et al: Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain. 2020, 21(1):32.
23. Raffaelli B, Kalantzis R, Mecklenburg J, Overeem LH, Neeb L, Gendolla A, et al: Erenumab in chronic migraine patients who previously failed five first-line oral prophylactics and onabotulinumtoxinA: a dual-center retrospective observational study. Front Neurol. 2020, 11: 417.
24. Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD, et al: Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 2018, 392(10161):2280-2287.
25. Russo A, Silvestro M, Scotto di Clemente F, Trojsi F, Bisecco A, Bonavita S, et al: Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience. J Headache Pain. 2020, 21(1):69.
26. Scheffler A, Messel O, Wurthmann S, Nsaka M, Kleinschnitz C, Glas M, et al: Erenumab in highly therapy-refractory migraine patients: first German real-world evidence. J Headache Pain. 2020, 21(1):84.
27. Tepper S, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein S, et al: Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017, 16(6):425-434.
28. American Headache Society: The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 2019, 59(1):1-18.
29. Leonard KV, Robertson C, Bhowmick A, Herbert LB: Perceived treatment satisfaction and effectiveness facilitators among patients with chronic health conditions: A self-reported survey. Interact J Med Res. 2020, 9(1):e13029.
30. Fang J, Korrer S, Johnson J, Vo P, Cheadle A, Shah R, et al: Real-world trends in characteristics of migraine patients newly initiated on erenumab in the United States. Eur J Neurology. 2020, 27(Suppl 1):103-522.EPR1098.
31. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF: Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007, 68(5):343-349.
32. Faust E, Pivneva I, Betts KA, Ahmed Z, Joshi S, Hogan R, et al: Treatment patterns & baseline characteristics of patients with migraine treated with erenumab: Interim analysis of a multicenter chart-review study. Headache. 2019, 59(S1):200.
33. Hines DM, Shah S, Multani JK, Wade RL, Buse DC, Bensink M: Erenumab prescription early view: Patient characteristics, treatment patterns, and adherence in the United States. Headache. 2019, 59(S1):199.
34. Bogdanov A, Chia V, Szekely C, Fischer L, Rasmussen S, Bensink ME, et al: Early use of erenumab in US real world practice. Headache. 2019, 59(S1):198.
35. Robbins L: CGRP monoclonal antibodies for chronic migraine. Pract Pain Manag. 2020, 19(6):58-62.